At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 65 enrolled
Drug / intervention
gabapentindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52 Weeks, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Gabapentin As Adjunctive Therapy In Pediatric Patients Who Have Completed The 12 Weeks Treatment In Study A9451162 (NCT00603473)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Feb 21, 2008·Updated Feb 3, 2021
In Brief
A Phase 3 clinical trial evaluating gabapentin for Epilepsies, Partial. Completed, enrolled 65 participants across 22 sites.
Detailed Summary
Examine the safety and efficacy of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsies, Partial
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartMay 2008
Primary CompletionDec 2010
TodayJul 2026
First PostedFeb 21, 2008
Enrollment StartMay 1, 2008
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.4 years ago
Interventions
gabapentindrug
Orally administered gabapentin